|Bid||71.17 x 1800|
|Ask||71.15 x 800|
|Day's Range||69.41 - 72.53|
|52 Week Range||20.57 - 136.50|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.40|
Shares of Fastly (NYSE: FSLY) were rising this morning as tech investors continued to shift their investing strategy after the Centers for Disease Control and Prevention and the Food and Drug Administration announced yesterday that they were recommending that the U.S. pause use of the Johnson & Johnson coronavirus vaccine. While there wasn't any company-specific news driving Fastly's share price higher today, some tech stocks started climbing yesterday in response to the U.S. pausing use of Johnson & Johnson's coronavirus vaccine. The FDA and CDC released a joint statement yesterday saying that "we are recommending a pause in the use of this vaccine out of an abundance of caution" after six individuals had reported cases of blood clots after receiving the Johnson & Johnson vaccine.
All three indexes have rocketed to new all-time highs, with the tech-heavy Nasdaq Composite leading the charge. At its best, the Nasdaq more than doubled in just 11 months' time. A number of factors, including sector rotation, higher Treasury yields, and valuation concerns, have weighed heavily on some of the market's growth stocks of late.
In the latest trading session, Fastly (FSLY) closed at $67.86, marking a -1.29% move from the previous day.